Seroprevalence of Pertussis in the Netherlands: Evidence for increased circulation of Bordetella pertussis

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  de Greeff, Sabine C ^a   de Melker, Hester E ^a   van Gageldonk, Pieter G M ^a   Schellekens, Joop F P ^b   van der Klis, Fiona R M ^a   Mollema, Liesbeth ^a   Mooi, Frits R ^a   Berbers, Guy A M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b Laboratory for Infectious Diseases   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS TOXIN; IMMUNOGLOBULIN G; PERTUSSIS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL TRANSMISSION; BORDETELLA PERTUSSIS; CHILD; CONTROLLED STUDY; COUGHING; CROSS-SECTIONAL STUDY; HUMAN; INFANT; INFECTION RATE; NETHERLANDS; NONHUMAN; PERTUSSIS; PRESCHOOL CHILD; SCHOOL CHILD; SEROPREVALENCE; VACCINATION; BLOOD; EPIDEMIOLOGY; FEMALE; IMMUNOASSAY; MALE; METABOLISM; MIDDLE AGED; NEWBORN;

BORDETELLA PERTUSSIS;

ADOLESCENT; ADULT; AGED; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NETHERLANDS; PERTUSSIS TOXIN; PERTUSSIS VACCINE; SEROEPIDEMIOLOGIC STUDIES; WHOOPING COUGH;

EID: 78649863908     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014183     Document Type: Article

References (36)

1. de Greeff SC, Mooi FR, Schellekens JF, de Melker HE (2008) Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J 27: 218-223.
2. de Melker HE, Schellekens JFP, Neppelenbroek SE, Mooi FR, Rumke HC, et al. (2000) Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis 6: 348-357.
3. Guris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, et al. (1999) Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 28: 1230-1237.
4. Hellenbrand W, Beier D, Jensen E, Littmann M, Meyer C, et al. (2009) The epidemiology of pertussis in Germany: past and present. BMC Infect Dis 9: 22.
5. Quinn HE, McIntyre PB (2007) Pertussis epidemiology in Australia over the decade 1995-2005-trends by region and age group. Commun Dis Intell 31: 205-215.
6. Berbers GAM, de Greeff SC, Mooi FR (2009) Improving pertussis vaccination. Hum Vaccin 5: 497-503.
7. He Q, Mertsola J (2008) Factors contributing to pertussis resurgence. Future Microbiol 3: 329-339.
8. Mooi FR (2010) Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol 10: 36-49.
9. van Lier EA, Oomen PJ, Oostenbrug MW, Zwakhals SL, Drijfhout IH, et al. (2009) [High vaccination coverage of the National Immunization Programme in the Netherlands]. Ned Tijdschr Geneeskd 153: 950-957.
10. Cherry JD (2005) The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 115: 1422-1427.
11. Teunis PF, van der Heijden OG, de Melker HE, Schellekens JF, Versteegh FG, et al. (2002) Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect 129: 479-489.
12. Versteegh FG, Mertens PL, de Melker HE, Roord JJ, Schellekens JF, et al. (2005) Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiol Infect 133: 737-748.
13. Giammanco A, Chiarini A, Maple PA, Andrews N, Pebody R, et al. (2003) European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine 22: 112-120.
14. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MAE, Elvers LH, Berbers GAM, et al. (2000) Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 38: 800-806.
15. Hallander HO, Gustafsson L, Ljungman M, Storsaeter J (2005) Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine 23: 5359-5364.
16. Hallander HO, Ljungman M, Storsaeter J, Gustafsson L (2009) Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. Apmis 117: 797-807.
17. Berbers GAM, Jones N (2008) Serologisch onderzoek naar het effect van de kinkhoestvaccinwisselingen in het RVP van 2004 tot 2008. Bilthoven: National Institute for Public Health and the Environment. 26 p.
18. de Melker HE, Conyn-van Spaendonck MA (1998) Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol Infect 121: 637-643.
19. van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA (2009) Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med 67: 301-308.
20. van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA (2008) Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 335: 79-89.
21. Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, et al. (1995) Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 96: 548-557.
22. Meade BD, Deforest A, Edwards KM, Romani TA, Lynn F, et al. (1995) Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 96: 570-575.
23. Nagel J, de Graaf S, Schijf-Evers D (1985) Improved serodiagnosis of whooping cough caused by Bordetella pertussis by determination of IgG anti-LPF antibody levels. Dev Biol Stand 61: 325-330.
24. de Melker HE, Versteegh FG, Schellekens JFP, Teunis PF, Kretzschmar M (2006) The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 53: 106-113.
25. Hendrikx LH, Berbers GA, Veenhoven RH, Sanders EA, Buisman AM (2009) IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine 27: 6530-6536.
26. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H (1997) Randomised controlled trial of two-component, three-component, and fivecomponent acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350: 1569-1577.
27. Pebody RG, Gay NJ, Giammanco A, Baron S, Schellekens J, et al. (2005) The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol Infect 133: 159-171.
28. Quinn HE, McIntyre PB, Backhouse JL, Gidding HF, Brotherton J, et al. (2009) The utility of seroepidemiology for tracking trends in pertussis infection. Epidemiol Infect 138: 426-433.
29. Hallander HO, Andersson M, Gustafsson L, Ljungman M, Netterlid E (2009) Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. Apmis 117: 912-922.
30. Mooi FR, Van Loo IHM, Van Gent M, He Q, Bart MJ, et al. (2009) Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerging Infectious Diseases 15(8): 1206-1213.
31. van Boven M, Mooi FR, Schellekens JF, de Melker HE, Kretzschmar M (2005) Pathogen adaptation under imperfect vaccination: implications for pertussis. Proc Biol Sci 272: 1617-1624.
32. Mooi FR, van Loo IH, King AJ (2001) Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis 7: 526-528.
33. de Greeff SC, Dekkers AL, Teunis P, Rahamat-Langendoen JC, Mooi FR, et al. (2009) Seasonal patterns in time series of pertussis. Epidemiol Infect 137: 1388-1395.
34. Forsyth K, Tan T, von Konig CH, Caro JJ, Plotkin S (2005) Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J 24: S69-74.
35. Aguas R, Goncalves G, Gomes MG (2006) Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect Dis 6: 112-117.
36. de Greeff SC, Mooi FR, Westerhof A, Verbakel JM, Peeters MF, et al. (2010) Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 50: 1339-1345.